Vinci-Biochem Srl
Via Ponte di Bagnolo, 10
50059 Vinci (Firenze) Italy

Tel: +39  0571 568 147 e 0571 568 135

anti-EGFR (L858R) (human), Rabbit Monoclonal (RM380)

  REV-31-1266-00-R100 100 µl

 
Synonyms: Epidermal Growth Factor Receptor; Proto-oncogene c-ErbB-1; Receptor Tyrosine-protein Kinase erbB-1
 
RevMab
anti-EGFR (L858R) (human), Rabbit Monoclonal (RM380)

Data Sheet:    

Reactivity
Human  

Applications
IHC  

Source / Host
Rabbit  

Specificity
This antibody reacts to human EGFR (L858R).  

Clone
RM380  

Purity
Protein A purified.  

Shipment
BLUE ICE  

Long Term Storage
-20°C  

Shelf Life
Stable for at least 1 year after receipt when stored at -20°C.  


Description
 
Recombinant Antibody. This antibody reacts to human EGFR (L858R). Applications: IHC. Source: Rabbit. Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. EGFR (Epidermal growth factor receptor, HER1, ErbB1) belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain (these include Y992, Y1045, Y1068, Y1148 and Y1173). Phosphorylation of EGF receptor (EGFR) at Tyr845 in the kinase domain is implicated in stabilizing the activation loop, maintaining the active state enzyme, and providing a binding surface for substrate proteins. The SH2 domain of PLCγ binds at phospho-Tyr992, resulting in activation of PLCγ-mediated downstream signaling. Phosphorylation of EGFR at Tyr1045 creates a major docking site for the adaptor protein c-Cbl, leading to receptor ubiquitination and degradation following EGFR activation. The GRB2 adaptor protein binds activated EGFR at phospho-Tyr1068. A pair of phosphorylated EGFR residues (Tyr1148 and Tyr1173) provide a docking site for the Shc scaffold protein, with both sites involved in MAP kinase signaling activation. Phosphorylation of EGFR at specific serine and threonine residues attenuates EGFR kinase activity. EGFR carboxy-terminal residues Ser1046 and Ser1047 are phosphorylated by CaM kinase II; mutation of either of these serines results in upregulated EGFR tyrosine autophosphorylation. EGFR activation signals multiple downstream signaling cascades such as the Ras - ERK, PI3K - Akt, Jak - STAT and PKC pathways that help in growth and proliferation of cells. Mutations in the EGFR gene (e.g. L858R) are associated with lung cancer and multiple alternatively spliced transcript variants encode different protein isoforms of EGFR have been found. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. Moreover, EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma. Deficient signaling of the EGFR and other receptor tyrosine kinases in humans is associated with diseases such as Alzheimer's.
 


 
 
 
 

ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
 
  • Come Contattarci - Contact Us:

    Semplicemente preferiamo che ci chiami o ci mandi una mail.
    E' anche possibile compilare il modulo contatti

    Vinci-Biochem Srl
    Via Ponte di Bagnolo, 10
    50059 Vinci (Firenze) Italy
    vb@vincibiochem.it
    Tel:+39 0571 568147
    P. IVA 05706610481
L o a d i n g